Summary
5-Fluorouracil (FUra) has emerged as the most promising clinical radiosensitizer now available. FUra's capacity to render human cells more sensitive to x-rays was established soon after its synthesis. However, the recognition that the drug's unusual pharmacology dictated explicit scheduling requirements in man was not realized until recently when work in the author's laboratory identified the extra-cellular drug concentration X time factors necessary to create the intra-cellular radiosensitive state. Subsequent clinico-pharmacologic investigations led to the realization that only prolonged continuous infusions combined with appropriately fractionated, cyclical radiation therapy would maximize the clinical utility of this approach. Infused FUra radiation-sensitization therapy reaches its maximum efficacy against the squamous-transitional cancers. This group of human malignancies comprises about 15% of all human cancers. Preliminary data also suggests substantial promise in the local/regional control of rectal and breast cancers. Infused FUra used as a radiosensitizer has the potential to eliminate the need for about 90% of all radical cancer surgery.
Similar content being viewed by others
References
Heidelberger C, Ansfield FJ: Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 23:1226–1243, 1963
Bagshaw M: Possible role of potentiators in radiation therapy. Amer J Roentgenol 85:822–833, 1961
Vietti T, Eggerding F, Valeriote F: Combined effect of x-radiation and 5-fluorouracil on survival of transplanted leukemia cells. J. Natl Cancer Inst 47:865–870, 1971
Moertel CG, Childs DS, Reitemeier RJ, et al.: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867, 1969
Lo TCM, Wiley Jr AL, Ansfield F, et al.: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Amer J Roentgenol 125:229–235, 1976
Gastrointestinal Tumour Study Group: A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 49: 1771–1777, 1982
Gastrointestinal Tumor Study Group: Prolongation of the disease free interval in surgically resected rectal cancer. New Eng J Med 312:1465–1472, 1985
Byfield JE, Chan PYM, Seagren SL: Radiosensitization by 5FU: Molecular origins and clinical scheduling implications. (Abstr) Proc Amer Assoc Ca Res 18:74, 1977
Byfield, JE, Calabro-Jones PM, Klisak I, et al.: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x-rays. Inter J Rad Oncol Biol Phys 8:1923–1933, 1982
Calabro-Jones PM, Byfield JE, Ward JF, et al.: Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cells in vitro. Cancer Res 42:4413–4420, 1982
Clarkson B, O'Connor A, Winston, La R, et al.: The physiologic disposition of 5-fluorouracil and 5-fluoro-2′-deoxyuridine in man. Clin Pharmacol Ther 5:581–610, 1962
Myers CE: The pharmacology of the fluoropyrimidines. Pharm Rev 33:1–15, 1981
Byfield JE, Sharp TR, Frankel SS, et al.: Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man. Amer J Clin Oncol 8:429–440, 1985
Valeriote F, Santelli G: 5-fluorouracil (FUra) Pharmacol Ther 24:107–132, 1984
Byfield JE, Frankel SS, Sharp TR, et al.: Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated radiation. Inter J Rad Oncol Biol Phys 11:791–800, 1985
Moertel CG, Schutt AJ, Reitemeier RJ, et al.: A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 32:2717–2719, 1972
Seifert P, Baker LH, Reed ML, et al.: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colo-rectal cancer. Cancer 36: 123–128, 1975
Lokich J, Bothe A, Fine N, et al.: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565–2568, 1981
Byfield JE, Sharp TR, Tang S, et al.: Phase I and II trial of cyclical 5-day infused 5-fluorouracil and coincident radiation in advanced cancer of the head of neck. J Clin Oncol 2: 406–413, 1983
Byfield JE: Theoretical basis and clinical applications of 5-fluorouracil used as a radiosensitizer. In: Rosenthal CJ, Rotman M (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Plenum Publishing Corp. New York, 1986, pp 113–125
Byfield JE: The clinical use of 5-fluorouracil and other halopyrimidines as radiosensitizers in man. In: Lokich J (ed) Cancer Chemotherapy by Infusion. Precept Press, Chicago, 1987, pp 479–501
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Byfield, J.E. 5-Fluorouracil radiation sensitization — A brief review. Invest New Drugs 7, 111–116 (1989). https://doi.org/10.1007/BF00178197
Issue Date:
DOI: https://doi.org/10.1007/BF00178197